Catégorie : News_Corporate
-
Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia
Drug candidate ABD-3001 is a galenic form of DIMATE, a first-in-class suicide inhibitor of aldehyde dehydrogenase 1 (ALDH1), being tested in relapsed patients with limited therapeutic options. Preliminary data from the First-in-human ODYSSEY study show that ABD-3001 was well tolerated, with activity of the drug candidate on its target, as well as proven biological activity,…
-
Advanced BioDesign joins forces with GTP Bioways to startmanufacturing of its innovative treatment for Acute MyeloidLeukemia (AML)
This partnership has been granted support from the Plan Innovation Santé 2030, a part ofthe France 2030 government program. ABD-3001 drug candidate is currently in phase I/II clinical development (ODYSSEY study) inrelapsed patients with limited therapeutic options. Lyon, Toulouse (France), March 27, 2024 – Advanced BioDesign, a biotech company specializing in the development of new…
-
Advanced BioDesign, winner of the France 2030 plan’s call for « i-DEMO » projects to finance its « Odyssey » clinical trial with up to €3M
Advanced BioDesign’s winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments.As part of the France 2030 plan, the « i-Demo » scheme supports the development of highly innovative, high added-value products and services to strengthen France’s scientific and technological capabilities. Lyon,…
